Angiotensin 1-7 (Ang 1-7)
Ang 1-7 is a 7-aa MAS receptor agonist produced by ACE2 that opposes the vasoconstrictive, fibrotic, and pro-inflammatory effects of Angiotensin II. Researched for hypertension, cardiac fibrosis, COVID-19, and neuroprotection.
Community Rating
No ratings yet
Compound Profile
Angiotensin 1-7 (Ang 1-7)
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. Angiotensin 1-7 (Ang 1-7) is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- MAS receptor agonism counteracts Ang II's vasoconstrictive and pro-fibrotic AT1R effects — a functional antihypertensive
- Anti-fibrotic: reduces TGF-β-driven cardiac, renal, and pulmonary fibrosis in preclinical models
- ACE2/Ang(1-7)/MAS axis is the counter-regulatory arm of the renin-angiotensin system (RAS)
- Angiotensin 1-7 (Ang 1-7) is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- MAS receptor agonism counteracts Ang II's vasoconstrictive and pro-fibrotic AT1R effects — a functional antihypertensive
- Anti-fibrotic: reduces TGF-β-driven cardiac, renal, and pulmonary fibrosis in preclinical models
- ACE2/Ang(1-7)/MAS axis is the counter-regulatory arm of the renin-angiotensin system (RAS)
- Neuroprotective in stroke and neurodegeneration models via MAS receptors in the brain
In Plain English
Simple summaryAngiotensin 1-7 (Ang 1-7) is a 7-amino acid peptide that's the 'good' side of the renin-angiotensin system (RAS) -- the blood pressure and fluid regulation pathway that angiotensin-converting enzyme (ACE) inhibitors and ARBs target. The traditional RAS story is: angiotensin II causes vasoconstriction and inflammation, which is why blocking its production or receptor is beneficial in heart failure and hypertension. Ang 1-7 is produced when ACE2 (the same enzyme COVID-19 uses as its entry receptor) cleaves angiotensin II, and it has opposite effects: vasodilation, anti-inflammatory signaling, cardiac protection, and improved insulin sensitivity. It acts through the Mas receptor, which was identified as an Ang 1-7 receptor in 2003 -- a discovery that opened an entire counter-regulatory RAS arm to research.
- MAS receptor agonism counteracts Ang II's vasoconstrictive and pro-fibrotic AT1R effects — a functional antihypertensive
- Anti-fibrotic: reduces TGF-β-driven cardiac, renal, and pulmonary fibrosis in preclinical models
- ACE2/Ang(1-7)/MAS axis is the counter-regulatory arm of the renin-angiotensin system (RAS)
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is Angiotensin 1-7 (Ang 1-7)?
Tap any underlined term for an instant definition.
Angiotensin 1-7 (Ang(1-7)) is a biologically active 7-amino acid peptide heptapeptide (Asp-Arg-Val-Tyr-Ile-His-Pro) that represents the counter-regulatory arm of the renin-angiotensin system (RAS). It is primarily generated by ACE2 (angiotensin-converting enzyme 2) cleavage of Angiotensin II (removing the C-terminal Phe8 residue), or by neprilysin and thimet oligopeptidase acting on Angiotensin I.
Ang(1-7) was identified as the endogenous ligand of the MAS receptor (MAS1 proto-oncogene) in a landmark 2003 Science paper by Santos et al. This discovery established the ACE2/Ang(1-7)/MAS axis as a distinct functional arm of the RAS, acting in opposition to the ACE/Ang II/AT1R axis.
**RAS balance:** - Classical axis: ACE → Angiotensin II → AT1R → vasoconstriction, aldosterone, inflammation, fibrosis, oxidative stress - Counter-regulatory axis: ACE2 → Ang(1-7) → MAS receptor → vasodilation, anti-inflammation, anti-fibrosis, natriuresis
**MAS receptor signaling:** MAS receptor is a GPCR (Gi-coupled) that, when activated by Ang(1-7): - Releases nitric oxide (vasodilation) - Activates MAPK ERK1/2 and PI3K/Akt (cardioprotection, anti-apoptosis) - Inhibits NF-κB → anti-inflammatory - Reduces TGF-β expression → anti-fibrotic
**COVID-19 relevance:** SARS-CoV-2 binds ACE2 to enter cells, effectively downregulating ACE2 expression and function. This reduces Ang(1-7) production while Ang II accumulates → exacerbated vasoconstriction, inflammation, and lung injury. The ACE2/Ang(1-7) axis is central to COVID-19 pathophysiology research, and Ang(1-7)-based therapies (TXA127, recombinant ACE2) are being studied as potential treatments for severe COVID-19-associated respiratory failure.
By the Numbers
Key Research Benefits
Documented effects observed in preclinical and clinical studies on Angiotensin 1-7 (Ang 1-7). See all Healing & Recovery peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Ang(1-7) human research protocols:
IV infusion studies: 0.5-3 nmol/kg/min (chronic heart failure studies, Feihl 2015) SC injection (preclinical): 24-72 mcg/kg/day via osmotic pump Investigational formulation: AVE0991 (non-peptide MAS agonist), NorLeu3-Ang(1-7) (stable analogue)
Human Phase II trials for heart failure (Grobe et al. 2007): continuous IV infusion targeting Ang(1-7) augmentation COVID-19-related research: Biosynthetic Ang(1-7) (TXA127) studied in Phase II for COVID-19 respiratory complications
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Ang(1-7) is used in research as an IV infusion or SC injection. Its rapid degradation by ACE and other peptidases limits utility without continuous delivery. Stable analogues or cyclodextrin-complexed forms extend duration of action.
What the research doesn't show
Ang 1-7's research profile is compelling but most human data is correlational (low Ang 1-7 correlates with worse cardiovascular outcomes) rather than interventional. Clinical trials of Ang 1-7 or its analogues (TXA127/TXA215) are ongoing but the results are preliminary. The ACE2-Ang 1-7 axis became much more research-active after COVID-19, so the field is moving but definitive human intervention data is still developing.
Medical Expert Videos
Physicians, researchers, and pharmacologists explain Angiotensin 1-7 (Ang 1-7), covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
Angiotensin 1-7 (Ang 1-7) has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: mas receptor agonism counteracts ang ii's vasoconstrictive and pro-fibrotic at1r effects — a functional antihypertensive.
The most commonly reported side effect in research subjects is generally well tolerated in phase i/ii human trials. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
How It Compares
Angiotensin II is the pro-inflammatory, vasoconstrictive counterpart that ACE inhibitors and ARBs target therapeutically. ACE inhibitors shift the balance toward Ang 1-7 as a secondary effect. BPC-157 also has cardiovascular protective effects through nitric oxide pathways. Ang 1-7's growing relevance is partly driven by COVID-19 research, where ACE2 downregulation by SARS-CoV-2 infection reduces Ang 1-7 production -- potentially contributing to the cardiovascular complications of COVID-19.
Compare Angiotensin 1-7 (Ang 1-7) side-by-sideResearch Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.